virus capsids

Affinia secures $1.6bn worth deal from Vertex to develop AAV capsids for genetic therapies
Pharmaceutical Business Review
Tue, 04/28/20 - 10:51 am
Affinia Therapeutics
R&D
Vertex Pharmaceuticals
virus capsids
gene therapy